All In Biotech

Drug Trial Radar · NCT02134028

Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study

Last checked: Nov 20, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,282

Actual

Start

Aug 5, 2014

Primary completion

Oct 11, 2019

Study completion Oct 11, 2019

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
May 8, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To evaluate the long-term safety and tolerability of dupilumab in participants with asthma who participated in a previous dupilumab asthma study (DRI12544, PDY14192, EFC13579, EFC13691). Secondary Objectives: To evaluate the long-term efficacy of dupilumab in participants with asthma who participated in a previous dupilumab asthma clinical study. To evaluate dupilumab in participants with asthma who participated in a previous dupilumab asthma clinical study, with regards to: * Systemic exposure * Anti-drug antibodies * Biomarkers

Conditions

  • Asthma

Interventions

  • DupilumabDrug

    Pharmaceutical form: Solution for injection Routes of administration: Subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)

Locations

365 sites in 27 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840047

    Birmingham, Alabama

  • Investigational Site Number 840099

    Gilbert, Arizona

  • Investigational Site Number 840087

    Scottsdale, Arizona

  • Investigational Site Number 840402

    Tucson, Arizona

  • Investigational Site Number 840132

    Little Rock, Arkansas

  • Investigational Site Number 840109

    Bakersfield, California

  • Investigational Site Number 840045

    Long Beach, California

  • Investigational Site Number 840019

    Los Angeles, California

  • Investigational Site Number 840029

    Los Angeles, California

  • Investigational Site Number 840022

    Los Angeles, California

  • Investigational Site Number 840044

    Newport Beach, California

  • Investigational Site Number 840041

    North Hollywood, California

  • Investigational Site Number 840014

    Rolling Hills Estates, California

  • Investigational Site Number 840121

    San Jose, California

  • Investigational Site Number 840040

    Colorado Springs, Colorado

  • Investigational Site Number 840403

    Denver, Colorado

  • Investigational Site Number 840006

    Denver, Colorado

  • Investigational Site Number 840024

    Denver, Colorado

  • Investigational Site Number 840130

    Denver, Colorado

  • Investigational Site Number 840902

    New Haven, Connecticut

  • Investigational Site Number 840137

    Aventura, Florida

  • Investigational Site Number 840071

    Gainesville, Florida

  • Investigational Site Number 840115

    Ocoee, Florida

  • Investigational Site Number 840055

    Sarasota, Florida

  • Investigational Site Number 840079

    Twin Falls, Idaho

  • Investigational Site Number 840101

    Chicago, Illinois

  • Investigational Site Number 840032

    Fort Mitchell, Kentucky

  • Investigational Site Number 840017

    Louisville, Kentucky

  • Investigational Site Number 840030

    Owensboro, Kentucky

  • Investigational Site Number 840064

    Bangor, Maine

  • Investigational Site Number 840052

    Chevy Chase, Maryland

  • Investigational Site Number 840073

    Gaithersburg, Maryland

  • Investigational Site Number 840080

    Owings Mills, Maryland

  • Investigational Site Number 840401

    Boston, Massachusetts

  • Investigational Site Number 840018

    Minneapolis, Minnesota

  • Investigational Site Number 840002

    St Louis, Missouri

  • Investigational Site Number 840102

    St Louis, Missouri

  • Investigational Site Number 840093

    St Louis, Missouri

  • Investigational Site Number 840037

    Missoula, Montana

  • Investigational Site Number 840078

    Omaha, Nebraska

Showing 40 of 365 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.